How current assay approval policies are leading to unintended imprecision medicine

Bookmark and Share
Published: 29 Oct 2020
Views: 339
Dr Roberto Salgado - Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium

Dr Roberto Salgado speaks to ecancer about the current assay approval policies and how they are leading to unintended imprecision medicine at the IBCD 2020 meeting held virtually this year.

Initially Dr Salgado talks about the problem of the PD-1 testing kit and how the presence of different testing kits for the same bio-marker are impacting bio-marker driven research.

Dr Salgado explains the reasons behind the current different thresholds in defining a positive marker and how they affect the world of cancer research and treatment.

He raises an important point saying that low and middle income countries are the most affected by this lack of unity in cancer testing kits and the global community needs to take heed of this issue and try to resolve it.

He further speaks of the challenges currently being faced by patients and oncologists and points out how the industry and the academic world can work together to standardise assays globally.

He winds it up by talking about the future of biomarker driven research and the important areas researchers and oncologists alike should be looking into.